For investors in Singapore

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE00BJJMRZ35

NAV
SGD 14.15
As of 2023/09/27

1-Day Change
SGD 0.04 (0.28%)
 As of 2023/09/27

Overview

OBJECTIVE AND INVESTMENT POLICY

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative & Annualised Performance (%)
As of 2023/08/31
I2 HSGD (Net) MSCI World Health Care NR
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2019/06/04
I2 HSGD (Net) -1.67 2.08 5.90 1.45 11.60 4.88 - - 9.54
MSCI World Health Care NR 0.93 3.38 6.64 2.00 6.58 6.31 - - 10.27
Past performance is not a guide to future performance. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
*Performance with sales charge assume 2.00% initial sales charge/front-end load (FEL) applied. 
© Morningstar 2023. All rights reserved. NAV-NAV, gross income reinvested where applicable.
The share class currency is different to the base currency of the Fund and its chosen benchmark. Past performance for this share class includes currency hedging which is not reflected in the performance of the benchmark.
Calendar Year Returns (%)
As of 2023/06/30
I2 HSGD (Net) MSCI World Health Care NR
2022 2021 2020
I2 HSGD (Net) -4.29 5.42 23.01
MSCI World Health Care NR -5.90 22.21 11.58
© Morningstar 2023. All rights reserved. NAV-NAV, gross income reinvested where applicable.
FEE INFORMATION
Initial Charge 2%
Annual Charge 1.5%
Ongoing Charge
(As of 2023/06/30) 		1.57%

Portfolio

Top Holdings (As of 2023/08/31)
% OF FUND
UnitedHealth Group Inc 6.09
Eli Lilly & Co 4.77
AstraZeneca PLC 3.93
Novo Nordisk A/S 3.58
Sanofi 2.94
Merck & Co Inc 2.83
Abbott Laboratories 2.63
AbbVie Inc 2.47
Sarepta Therapeutics Inc 2.44
Thermo Fisher Scientific Inc 2.43
Total 34.11
Sector Allocation % OF FUND % OF FUND (As of 2023/08/31)
Regional Allocation % OF FUND % OF FUND (As of August 31, 2023)

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Hiding in plain sight: The investment case for healthcare
Sep 11, 2023
Timely & Topical

Hiding in plain sight: The investment case for healthcare

Why attractive valuations and new growth opportunities make healthcare worthy of another look by investors.

7 min read

JH Explorer in San Diego: The future of treating diabetes
Aug 23, 2023
Timely & Topical

JH Explorer in San Diego: The future of treating diabetes

A new approach to treating diabetes could lead to weight loss and cardiovascular benefits, unlocking the potential for significant growth.

4 min read

Keeping perspective on AI’s role in biotech
Jun 15, 2023
Timely & Topical

Keeping perspective on AI’s role in biotech

While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.

3 min read